Application of crizotinib in preparation of medicines capable of resisting gram-positive bacteria

An anti-Gram-positive, Gram-positive technology, applied in the field of biomedicine, can solve the problem of no crizotinib to inhibit bacteria, etc., and achieve the effect of reliable pharmacological safety, growth inhibition and remarkable effect

Active Publication Date: 2020-01-07
JINAN UNIVERSITY
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] But so far, there is no relevant report on the research on the inhibition of bacteria by crizotinib

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of crizotinib in preparation of medicines capable of resisting gram-positive bacteria
  • Application of crizotinib in preparation of medicines capable of resisting gram-positive bacteria
  • Application of crizotinib in preparation of medicines capable of resisting gram-positive bacteria

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] The antibacterial spectrum research of embodiment 1 crizotinib

[0040] This example studies the antibacterial spectrum of crizotinib.

[0041]Tested strains: Streptococcus pneumoniae (S.pneumoniae D39) was purchased from China Type Culture Collection; Streptococcus suis (S.suis BM407), Staphylococcus aureus (S.aureus 29213), MRSA (S.aureus ATCC43300) Bacillus subtilis (B.subtilis 2508) was purchased from the Microbial Culture Collection Center of China; Bacillus subtilis (B.subtilis 2508) was purchased from the Guangdong Provincial Microbial Culture Collection Center; The bacterium (P.aeruginosa ATCC9027) was obtained from the American Type Culture Collection, and the minimum inhibitory concentration (MIC) of the model was determined (three single clones of each strain).

[0042] 1. Experimental steps

[0043] Streptococcus pneumoniae was inoculated into 0.5% THYE liquid medium for overnight activation according to the inoculum amount of 5%, and then transferred to f...

Embodiment 2

[0051] Embodiment 2 crizotinib is measured to Staphylococcus aureus minimum inhibitory concentration (MIC)

[0052] The tested strains of this embodiment: Staphylococcus aureus methicillin-resistant strain MRSA (ATCC43300) and the sensitive strain of Staphylococcus aureus (29213) are from the General Microbiology Center of China Committee for Culture Collection of Microorganisms; Staphylococcus aureus single Nike Linmycin strain (29213-K), Staphylococcus aureus single-resistant gentamicin strain (29213-G), Staphylococcus aureus single-resistant ciprofloxacin strain (29213-C), Staphylococcus aureus single-resistant Amoxicillin (29213-A), Staphylococcus aureus single-resistant levofloxacin strain (29213-L) is domesticated from a sensitive strain of Staphylococcus aureus (29213).

[0053] Among them, Staphylococcus aureus single-resistant clindamycin strain (29213-K), Staphylococcus aureus single-resistant gentamycin strain (29213-G), Staphylococcus aureus single-resistant ciprof...

Embodiment 3

[0063] The minimum inhibitory concentration (MIC) determination of embodiment 3 crizotinib to clinically isolated multidrug-resistant Staphylococcus aureus, Enterococcus faecalis, Staphylococcus hemolyticus

[0064] The tested bacterial strain of this embodiment is clinically isolated multi-drug resistant Staphylococcus aureus (168272, 168023, 166471, 166534, 166138, 168293, 900624, 168205, 179634, 179148, 179475, 179459, 178425, 178524, 178360) , Enterococcus faecalis (179521), and Staphylococcus hemolyticus (179595), from the Laboratory Department of Southern Medical University. The above numbers are the system numbers of the corresponding strains in the Laboratory Department of Southern Medical University. The drug resistance of related strains is shown in Table 3.

[0065] Table 3 Drug resistance of related strains (MIC unit: μg / mL)

[0066]

[0067]

[0068] 1. Experimental steps

[0069] The clinically isolated multi-drug-resistant Staphylococcus aureus, Enterococ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Minimum inhibitory concentrationaaaaaaaaaa
Minimum inhibitory concentrationaaaaaaaaaa
Login to view more

Abstract

The invention provides application of crizotinib in preparation of medicines capable of resisting gram-positive bacteria. For the first time, it is proposed that an anti-tumor drug, namely the clozatinib, can effectively inhibit gram-positive bacteria; and the clozatinib is particularly significant in the effect of inhibiting growth of single drug resistant strains and clinical multi-drug-resistant strains, as well as wide in anti-bacterial spectrum. Thus, application range of the crizotinib is expanded, so that the crizotinib has the potential to be developed into anti-bacterial medicines. The clozatinib is a drug which has been approved for marketing by drug regulatory authorities in many countries around the world, so that no more toxicological experiment is required due to more reliable pharmacological safety; and thus, the clozatinib is excellent in development and utilization prospects. The application of the crizotinib in preparation of the medicines capable of resisting the gram-positive bacteria is of important practical significance to treatment of gram-positive bacterial infection (and especially for drug-resistant bacterial infection), so that a new drug choice is provided for clinical treatment of the gram-positive bacterial infection.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of crizotinib in the preparation of anti-gram-positive bacteria drugs. Background technique [0002] For a long time, infectious diseases caused by pathogenic microorganisms have been an important factor that endangers human health. Pathogenic bacterial infection is an acute systemic infection caused by pathogenic bacteria or opportunistic pathogenic bacteria invading the blood circulation to grow and reproduce, producing toxins and other metabolites, especially for the elderly, children, those with chronic diseases or low immune function, and those who are not treated in time And those with complications may develop sepsis or sepsis and die. At present, antibiotics are commonly used clinically to inhibit bacteria, and antibiotics have also brought great changes to the treatment of infectious diseases. Due to the overuse and inappropriate application of ant...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4545A61P31/04
CPCA61K31/4545A61P31/04
Inventor 孙雪松郑云丹
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap